CLAIMS

1. An isolated antibody, or an antigen binding fragment thereof, comprising the CDR1, CDR2, and CDR3 sequences of the heavy and/or light chain variable region sequences set forth respectively in SEQ ID NOs: 39 and 40.

2. An isolated antibody, or an antigen binding fragment thereof, comprising heavy chain variable region CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 33, 34, and 35, respectively, and/or light chain variable region CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 36, 37, and 38, respectively.

3. The antibody or fragment of claim 1, comprising the heavy and/or light chain variable region sequences set forth in SEQ ID NOs. 39 and 40, respectively.

4. An isolated antibody, or antigen binding fragment thereof, that competes with or binds to the same epitope as an antibody comprising the heavy and light chain variable region sequences set forth in SEQ ID NO: 39 and 40, respectively.

5. The antibody or fragment of any one of claims 1-4, that is specific for a complex of human cytomegalovirus (hCMV) proteins UL130 and UL131A.

6. The antibody or fragment of any one of claims 1-5, which inhibits infection of epithelial cells, wherein the concentration of antibody required for 50% inhibition of hCMV is 10 μg/ml or less.

7. The antibody or fragment of claim 6, wherein the concentration of antibody required for 50% inhibition of hCMV is 0.2 μg/ml or less.

8. The antibody or fragment of claim 6, wherein the concentration of antibody required for 50% inhibition of hCMV is 0.1 μg/ml or less.

9. The antibody or fragment of claim 6, wherein the concentration of antibody required for 50% inhibition of hCMV is 0.01 μg/ml.

10. The antibody or fragment of any one of claims 1-9, wherein the antibody is a human antibody, a monoclonal antibody, a single chain antibody, Fab, Fab', F(ab')2, Fv or scFv.

11. A composition comprising the antibody or fragment of any one of claims 1-10, and a diluent or carrier.

12. The composition of claim 11, further comprising a second antibody, or an antigen binding fragment thereof, which inhibits hCMV infection.

13. The composition of claim 12, wherein the second antibody binds to an hCMV gB protein.

14. Use of an effective amount of the antibody of any one of claims 1-10, or antigen binding portion thereof, in the manufacture of a medicament for the inhibition of human cytomegalovirus (hCMV) infection in a subject.

15. The use of claim 14, further comprising a second antibody, or an antigen binding fragment thereof, which inhibits hCMV infection.

16. The use of claim 15, wherein the second antibody binds to an hCMV gB protein.

17. A method of inhibiting hCMV infection in a cell *in vitro*, comprising contacting the cell with the antibody of claim 1 or 4, or antigen binding portion thereof.

CLAIMS

1. Use of an effective amount of an antibody, or antigen binding portion thereof, in the manufacture of a medicament for the inhibition of human cytomegalovirus (hCMV) infection in a subject, wherein the said antibody, or antigen binding portion thereof, comprises heavy and light chain variable region CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, respectively.

2. Use of an effective amount of an antibody, or antigen binding portion thereof, in the manufacture of a medicament for the inhibition of human cytomegalovirus (hCMV) infection in a subject, wherein the said antibody, or antigen binding portion thereof comprises heavy and light chain variable regions comprising the amino acid sequence of SEQ ID NO: 7 and SEQ ID NO: 8, respectively.

3. Use of an effective amount of an antibody, or antigen binding portion thereof, in the manufacture of a medicament for the inhibition of human cytomegalovirus (hCMV) infection in a subject, wherein the said antibody, or antigen binding portion thereof, binds to the same epitope as an antibody having heavy and light chain variable regions comprising the amino acid sequence of SEQ ID NO: 7 and SEQ ID NO: 8, respectively.

4. The use of claim 2, wherein the antibody is human monoclonal antibody 1F11.

5. The use of claim 1, 2, or 3, wherein the antibody is a human antibody, a monoclonal antibody, a human monoclonal antibody, a single chain antibody, Fab, Fab′, $F(ab')_2$, Fv or scFv.

6. The use of claim 1, 2, or 3, further comprising the administration of a second antibody, or antigen binding fragment thereof, which inhibits hCMV infection.

7. The use of claim 6, wherein the second antibody, or antigen binding portion thereof, is specific for hCMV protein gB.

8. The use of claim 1, 2, or 3, wherein the antibody is specific for a complex comprising hCMV proteins UL130 and UL131A and inhibits infection of endothelial cells, retinal

cells, or dendritic cells by hCMV, wherein the concentration of antibody required for 50% inhibition of hCMV is 0.3 μg/ml or less.

9. The use of claim 8, wherein the concentration of antibody required for 50% inhibition of hCMV is 0.01 μg/ml or less.

10. The use of claim 8, wherein the concentration of antibody required for 50% inhibition of hCMV is 0.003 μg/ml or less.

11. The use of claim 8, wherein the antibody binds a conformational epitope formed by the two proteins.